PharmaEssentia
MA - BurlingtonBiotechnology
Focus: PharmaEssentia is a biotechnology company focused on biologic therapies in hematology, oncology, infectious diseases, and immunology, headquartered in Burlington, MA since 2003. The company is heavily dependent on BESREMI, a pegylated interferon alpha-2b treatment for myeloproliferative neoplasms.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About PharmaEssentia
AI assessmentNot HiringNo open roles listed right now. Follow PharmaEssentia to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
10 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Peak
Sole revenue-generating product; pegylated interferon with JAK/STAT mechanism targeting myeloproliferative neoplasms.
Products & Portfolio (1)
Help build intelligence for PharmaEssentia
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.